This is the Pro digest exactly as subscribers received it on Sep 15, 2026: what changed, every setup with its bottom line and confirm/invalidate criteria, and every analyst note in full with the red-team caveats. The CSV of the whole screener is attached to the real thing. Sample refreshes monthly.
Since yesterday: 3 exchange deficiency & delisting notices, 9 new shelves & offerings across 1,398 US microcaps. Highest-pressure setup this morning: DAIC (CID Holdco, Inc.) — Listing is at risk and the usual cures are constrained. On the support side, KPLT — A new active holder crossed 5% and must state its intentions.
Every item links to the SEC filing. Direction is stated for existing shareholders (▼ pressure: more shares, survival or listing risk · ▲ support: insiders or holders buying). Research, not advice.
Pressure ▼ — dilution, listing and survival risk for existing holders, ranked by Radar.
DAIC · CID Holdco, Inc. — Pressure ▼ · Radar 97 · runway 0.8 mo · Listing cliff
Listing is at risk and the usual cures are constrained. Next thing to watch: a reverse-split proxy, a hearings-panel 8-K, or a Form 25.
Key filing: Default / acceleration, Aug 18, 2026 — 8-K Item 2.04 filed 2026-08-18 (accepted 17:02 ET) (filing) - MVLS deficiency · 2026-08-18: “mvls deficiency” language in 8-K (8-K) filed 2026-08-18 (filing) - MVLS deficiency · 2026-09-01: “mvls deficiency” language in 8-K (EX-99.1) filed 2026-09-01 (filing) - Hearings panel · 2026-08-18: “hearings panel” language in 8-K (8-K) filed 2026-08-18 (filing) Would confirm: Nasdaq 'Pending Suspension' listing, Form 25, hearings-panel denial 8-K, or a reverse-split proxy. · Would invalidate: 8-K announcing regained compliance; equity raise that restores stockholders' equity; MVLS back above threshold for 10+ days.
AUID · authID Inc. — Pressure ▼ · Radar 97 · runway 1.2 mo · Listing cliff
Listing is at risk and the usual cures are constrained. Next thing to watch: a reverse-split proxy, a hearings-panel 8-K, or a Form 25.
Key filing: Exchange deficiency notice, Aug 21, 2026 — 8-K Item 3.01 filed 2026-08-21 (accepted 17:00 ET) (filing) - MVLS deficiency · 2026-08-21: “mvls deficiency” language in 8-K (8-K) filed 2026-08-21 (filing) - Hearings panel · 2026-08-21: “hearings panel” language in 8-K (8-K) filed 2026-08-21 (filing) - Hearings panel · 2026-09-01: “hearings panel” language in 8-K (8-K) filed 2026-09-01 (filing) Would confirm: Nasdaq 'Pending Suspension' listing, Form 25, hearings-panel denial 8-K, or a reverse-split proxy. · Would invalidate: 8-K announcing regained compliance; equity raise that restores stockholders' equity; MVLS back above threshold for 10+ days.
DFLI · Dragonfly Energy Holdings Corp. — Pressure ▼ · Radar 95 · runway 3.5 mo · Listing cliff
Listing is at risk and the usual cures are constrained. Next thing to watch: a reverse-split proxy, a hearings-panel 8-K, or a Form 25.
Key filing: Exchange deficiency notice, Aug 21, 2026 — 8-K Item 3.01 filed 2026-08-21 (accepted 17:00 ET) (filing) - MVLS deficiency · 2026-08-21: “mvls deficiency” language in 8-K (8-K) filed 2026-08-21 (filing) - Hearings panel · 2026-08-21: “hearings panel” language in 8-K (8-K) filed 2026-08-21 (filing) - Equity deficiency · 2026-08-21: “stockholders equity deficiency” language in 8-K (8-K) filed 2026-08-21 (filing) Would confirm: Nasdaq 'Pending Suspension' listing, Form 25, hearings-panel denial 8-K, or a reverse-split proxy. · Would invalidate: 8-K announcing regained compliance; equity raise that restores stockholders' equity; MVLS back above threshold for 10+ days.
SOBR · SOBR Safe, Inc. — Pressure ▼ · Radar 95 · runway 0.6 mo · Forced raise, Listing cliff
The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K.
Key filing: MVLS deficiency, Aug 27, 2026 — “mvls deficiency” language in 8-K (8-K) filed 2026-08-27 (filing) - Hearings panel · 2026-08-27: “hearings panel” language in 8-K (8-K) filed 2026-08-27 (filing) - Equity deficiency · 2026-08-27: “stockholders equity deficiency” language in 8-K (8-K) filed 2026-08-27 (filing) - Exchange deficiency notice · 2026-08-27: 8-K Item 3.01 filed 2026-08-27 (accepted 17:00 ET) (filing) Would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it. · Would invalidate: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).
ISPC · iSpecimen Inc. — Pressure ▼ · Radar 95 · runway 6.4 mo · Listing cliff
Listing is at risk and the usual cures are constrained. Next thing to watch: a reverse-split proxy, a hearings-panel 8-K, or a Form 25.
Key filing: MVLS deficiency, Sep 10, 2026 — “mvls deficiency” language in 8-K (8-K) filed 2026-09-10 (filing) - Hearings panel · 2026-09-10: “hearings panel” language in 8-K (8-K) filed 2026-09-10 (filing) - Equity deficiency · 2026-09-10: “stockholders equity deficiency” language in 8-K (8-K) filed 2026-09-10 (filing) - Exchange deficiency notice · 2026-09-10: 8-K Item 3.01 filed 2026-09-10 (accepted 17:00 ET) (filing) Would confirm: Nasdaq 'Pending Suspension' listing, Form 25, hearings-panel denial 8-K, or a reverse-split proxy. · Would invalidate: 8-K announcing regained compliance; equity raise that restores stockholders' equity; MVLS back above threshold for 10+ days.
TRUG · TruGolf Holdings, Inc. — Pressure ▼ · Radar 95 · runway n/a · Listing cliff, Death-spiral watch
Listing is at risk and the usual cures are constrained. Next thing to watch: a reverse-split proxy, a hearings-panel 8-K, or a Form 25.
Key filing: Exchange deficiency notice, Aug 21, 2026 — 8-K Item 3.01 filed 2026-08-21 (accepted 17:18 ET) (filing) - MVLS deficiency · 2026-08-18: “mvls deficiency” language in 8-K (EX-99.1) filed 2026-08-18 (filing) - Equity deficiency · 2026-08-21: “stockholders equity deficiency” language in 8-K (8-K) filed 2026-08-21 (filing) - Equity line · 2026-08-18: “equity line” language in 8-K (EX-10.1) filed 2026-08-18 (filing) Would confirm: Nasdaq 'Pending Suspension' listing, Form 25, hearings-panel denial 8-K, or a reverse-split proxy. · Would invalidate: 8-K announcing regained compliance; equity raise that restores stockholders' equity; MVLS back above threshold for 10+ days.
LIMN · Liminatus Pharma, Inc. — Pressure ▼ · Radar 95 · runway 0.0 mo · Listing cliff
Listing is at risk and the usual cures are constrained. Next thing to watch: a reverse-split proxy, a hearings-panel 8-K, or a Form 25.
Key filing: MVLS deficiency, Aug 18, 2026 — “mvls deficiency” language in 8-K (8-K) filed 2026-08-18 (filing) - Hearings panel · 2026-08-18: “hearings panel” language in 8-K (8-K) filed 2026-08-18 (filing) - Exchange deficiency notice · 2026-08-18: 8-K Item 3.01 filed 2026-08-18 (accepted 16:06 ET) (filing) - Minimum bid deficiency · 2026-08-18: “min bid” language in 8-K (8-K) filed 2026-08-18 (filing) Would confirm: Nasdaq 'Pending Suspension' listing, Form 25, hearings-panel denial 8-K, or a reverse-split proxy. · Would invalidate: 8-K announcing regained compliance; equity raise that restores stockholders' equity; MVLS back above threshold for 10+ days.
GOVX · GeoVax Labs, Inc. — Pressure ▼ · Radar 94 · runway 2.6 mo · Forced raise, Listing cliff, Death-spiral watch
The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K.
Key filing: Exchange deficiency notice, Aug 28, 2026 — 8-K Item 3.01 filed 2026-08-28 (accepted 16:16 ET) (filing) - Hearings panel · 2026-08-28: “hearings panel” language in 8-K (8-K) filed 2026-08-28 (filing) - Equity deficiency · 2026-08-28: “stockholders equity deficiency” language in 8-K (8-K) filed 2026-08-28 (filing) - Equity line · 2026-08-28: “equity line” language in 8-K (EX-10.1) filed 2026-08-28 (filing) Would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it. · Would invalidate: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).
ADIL · Adial Pharmaceuticals, Inc. — Pressure ▼ · Radar 94 · runway 21.3 mo · Forced raise, Listing cliff
The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K.
Key filing: Exchange deficiency notice, Aug 21, 2026 — 8-K Item 3.01 filed 2026-08-21 (accepted 17:17 ET) (filing) - MVLS deficiency · 2026-08-21: “mvls deficiency” language in 8-K (8-K) filed 2026-08-21 (filing) - Equity deficiency · 2026-08-21: “stockholders equity deficiency” language in 8-K (8-K) filed 2026-08-21 (filing) - Delisting language · 2026-08-21: “delisting notice” language in 8-K (8-K) filed 2026-08-21 (filing) Would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it. · Would invalidate: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).
BRTX · BioRestorative Therapies, Inc. — Pressure ▼ · Radar 94 · runway 4.0 mo · Listing cliff, Reporting stress
Listing is at risk and the usual cures are constrained. Next thing to watch: a reverse-split proxy, a hearings-panel 8-K, or a Form 25.
Key filing: Auditor change, Sep 2, 2026 — 8-K Item 4.01 filed 2026-09-02 (accepted 18:09 ET) (filing) - Exchange deficiency notice · 2026-08-25: 8-K Item 3.01 filed 2026-08-25 (accepted 17:00 ET) (filing) - Departure cluster · 2026-09-11: 3 Item 5.02 8-Ks in 90 days (latest 2026-09-11) (filing) - Hearings panel · 2026-08-25: “hearings panel” language in 8-K (8-K) filed 2026-08-25 (filing) Would confirm: Nasdaq 'Pending Suspension' listing, Form 25, hearings-panel denial 8-K, or a reverse-split proxy. · Would invalidate: 8-K announcing regained compliance; equity raise that restores stockholders' equity; MVLS back above threshold for 10+ days.
SNTI · Senti Biosciences Holdings, Inc. — Pressure ▼ · Radar 94 · runway 3.5 mo · Forced raise, Listing cliff, Death-spiral watch
The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K.
Key filing: Exchange deficiency notice, Sep 2, 2026 — 8-K Item 3.01 filed 2026-09-02 (accepted 16:29 ET) (filing) - Hearings panel · 2026-09-02: “hearings panel” language in 8-K (8-K) filed 2026-09-02 (filing) - Equity deficiency · 2026-09-02: “stockholders equity deficiency” language in 8-K (8-K) filed 2026-09-02 (filing) - Minimum bid deficiency · 2026-09-02: “min bid” language in 8-K (8-K) filed 2026-09-02 (filing) Would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it. · Would invalidate: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).
DVLT · Datavault AI Inc. — Pressure ▼ · Radar 94 · runway 1.1 mo · Forced raise, Listing cliff, Death-spiral watch
The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K.
Key filing: Hearings panel, Aug 25, 2026 — “hearings panel” language in 8-K (8-K) filed 2026-08-25 (filing) - Exchange deficiency notice · 2026-08-25: 8-K Item 3.01 filed 2026-08-25 (accepted 16:25 ET) (filing) - Offering (424B) · 2026-08-19: 424B5 prospectus supplement 2026-08-19; 9 prior 424B filings in 12m (filing) - Minimum bid deficiency · 2026-08-25: “min bid” language in 8-K (8-K) filed 2026-08-25 (filing) Would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it. · Would invalidate: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).
PFSA · Profusa, Inc. — Mixed ◆ · Radar 94 · runway 0.3 mo · Forced raise, Listing cliff, Death-spiral watch, Activist + distress
The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K.
Key filing: Equity line, Aug 21, 2026 — “equity line” language in 8-K (EX-10.2) filed 2026-08-21 (filing) - Equity line · 2026-09-01: “equity line” language in 8-K (EX-10.1) filed 2026-09-01 (filing) - Exchange deficiency notice · 2026-08-31: 8-K Item 3.01 filed 2026-08-31 (accepted 08:54 ET) (filing) - Delisting language · 2026-08-31: “delisting notice” language in 8-K (8-K) filed 2026-08-31 (filing) Would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it. · Would invalidate: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).
RAIN · Rain Enhancement Technologies Holdco, In — Pressure ▼ · Radar 94 · runway 0.1 mo · Listing cliff
Listing is at risk and the usual cures are constrained. Next thing to watch: a reverse-split proxy, a hearings-panel 8-K, or a Form 25.
Key filing: MVLS deficiency, Aug 21, 2026 — “mvls deficiency” language in 8-K (8-K) filed 2026-08-21 (filing) - Hearings panel · 2026-08-21: “hearings panel” language in 8-K (8-K) filed 2026-08-21 (filing) - Exchange deficiency notice · 2026-08-21: 8-K Item 3.01 filed 2026-08-21 (accepted 16:30 ET) (filing) - Delisting language · 2026-08-21: “delisting notice” language in 8-K (8-K) filed 2026-08-21 (filing) Would confirm: Nasdaq 'Pending Suspension' listing, Form 25, hearings-panel denial 8-K, or a reverse-split proxy. · Would invalidate: 8-K announcing regained compliance; equity raise that restores stockholders' equity; MVLS back above threshold for 10+ days.
GCTK · Glucotrack, Inc. — Pressure ▼ · Radar 94 · runway 0.9 mo · Forced raise, Listing cliff, Death-spiral watch
The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K.
Key filing: Equity line, Sep 11, 2026 — “equity line” language in 8-K (EX-10.1) filed 2026-09-11 (filing) - Hearings panel · 2026-08-27: “hearings panel” language in 8-K (EX-99.1) filed 2026-08-27 (filing) - Equity line · 2026-08-28: “equity line” language in 8-K/A (EX-99.4) filed 2026-08-28 (filing) - Equity line · 2026-09-14: “equity line” language in 8-K (8-K) filed 2026-09-14 (filing) Would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it. · Would invalidate: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).
NXL · Nexalin Technology, Inc. — Mixed ◆ · Radar 94 · runway 1.7 mo · Forced raise, Listing cliff, Death-spiral watch, Shelf loaded, Activist + distress
The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K.
Key filing: Equity deficiency, Aug 17, 2026 — “stockholders equity deficiency” language in 8-K (8-K) filed 2026-08-17 (filing) - Equity line · 2026-08-21: “equity line” language in 8-K (EX-10.2) filed 2026-08-21 (filing) - Equity line · 2026-08-20: “equity line” language in 8-K (EX-10.2) filed 2026-08-20 (filing) - Exchange deficiency notice · 2026-08-17: 8-K Item 3.01 filed 2026-08-17 (accepted 09:00 ET) (filing) Would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it. · Would invalidate: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).
JUNS · Jupiter Neurosciences, Inc. — Pressure ▼ · Radar 94 · runway n/a · Forced raise, Listing cliff, Death-spiral watch
The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K.
Key filing: Departure cluster, Aug 27, 2026 — 3 Item 5.02 8-Ks in 90 days (latest 2026-08-27) (filing) - Exchange deficiency notice · 2026-08-28: 8-K Item 3.01 filed 2026-08-28 (accepted 16:05 ET) (filing) - Hearings panel · 2026-08-28: “hearings panel” language in 8-K (8-K) filed 2026-08-28 (filing) - Offering (424B) · 2026-08-24: 424B5 prospectus supplement 2026-08-24; 13 prior 424B filings in 12m (filing) Would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it. · Would invalidate: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).
SCKT · Socket Mobile, Inc. — Pressure ▼ · Radar 93 · runway 15.0 mo · Listing cliff
Listing is at risk and the usual cures are constrained. Next thing to watch: a reverse-split proxy, a hearings-panel 8-K, or a Form 25.
Key filing: MVLS deficiency, Aug 28, 2026 — “mvls deficiency” language in 8-K (8-K) filed 2026-08-28 (filing) - Hearings panel · 2026-08-28: “hearings panel” language in 8-K (8-K) filed 2026-08-28 (filing) - Exchange deficiency notice · 2026-08-28: 8-K Item 3.01 filed 2026-08-28 (accepted 13:03 ET) (filing) - Equity deficiency · 2026-08-28: “stockholders equity deficiency” language in 8-K (8-K) filed 2026-08-28 (filing) Would confirm: Nasdaq 'Pending Suspension' listing, Form 25, hearings-panel denial 8-K, or a reverse-split proxy. · Would invalidate: 8-K announcing regained compliance; equity raise that restores stockholders' equity; MVLS back above threshold for 10+ days.
RKDA · Arcadia Biosciences, Inc. — Pressure ▼ · Radar 93 · runway 17.4 mo · Listing cliff
Listing is at risk and the usual cures are constrained. Next thing to watch: a reverse-split proxy, a hearings-panel 8-K, or a Form 25.
Key filing: MVLS deficiency, Sep 4, 2026 — “mvls deficiency” language in 8-K (8-K) filed 2026-09-04 (filing) - Exchange deficiency notice · 2026-09-04: 8-K Item 3.01 filed 2026-09-04 (accepted 16:05 ET) (filing) - Hearings panel · 2026-09-04: “hearings panel” language in 8-K (8-K) filed 2026-09-04 (filing) - Equity deficiency · 2026-09-04: “stockholders equity deficiency” language in 8-K (8-K) filed 2026-09-04 (filing) Would confirm: Nasdaq 'Pending Suspension' listing, Form 25, hearings-panel denial 8-K, or a reverse-split proxy. · Would invalidate: 8-K announcing regained compliance; equity raise that restores stockholders' equity; MVLS back above threshold for 10+ days.
SMXT · SolarMax Technology, Inc. — Pressure ▼ · Radar 93 · runway 3.0 mo · Listing cliff
Listing is at risk and the usual cures are constrained. Next thing to watch: a reverse-split proxy, a hearings-panel 8-K, or a Form 25.
Key filing: MVLS deficiency, Aug 21, 2026 — “mvls deficiency” language in 8-K (8-K) filed 2026-08-21 (filing) - Exchange deficiency notice · 2026-08-21: 8-K Item 3.01 filed 2026-08-21 (accepted 17:15 ET) (filing) - Late filing (NT) · 2026-08-17: NT 10-Q filed 2026-08-17 (filing) - Minimum bid deficiency · 2026-08-21: “min bid” language in 8-K (8-K) filed 2026-08-21 (filing) Would confirm: Nasdaq 'Pending Suspension' listing, Form 25, hearings-panel denial 8-K, or a reverse-split proxy. · Would invalidate: 8-K announcing regained compliance; equity raise that restores stockholders' equity; MVLS back above threshold for 10+ days.
SHPH · Shuttle Pharmaceuticals Holdings, Inc. — Pressure ▼ · Radar 93 · runway 1.4 mo · Listing cliff
Listing is at risk and the usual cures are constrained. Next thing to watch: a reverse-split proxy, a hearings-panel 8-K, or a Form 25.
Key filing: Exchange deficiency notice, Aug 28, 2026 — 8-K Item 3.01 filed 2026-08-28 (accepted 16:45 ET) (filing) - Hearings panel · 2026-08-28: “hearings panel” language in 8-K (8-K) filed 2026-08-28 (filing) - Late filing (NT) · 2026-08-17: NT 10-Q filed 2026-08-17 (filing) - Delisting language · 2026-08-28: “delisting notice” language in 8-K (8-K) filed 2026-08-28 (filing) Would confirm: Nasdaq 'Pending Suspension' listing, Form 25, hearings-panel denial 8-K, or a reverse-split proxy. · Would invalidate: 8-K announcing regained compliance; equity raise that restores stockholders' equity; MVLS back above threshold for 10+ days.
ESLA · Estrella Immunopharma, Inc. — Pressure ▼ · Radar 93 · runway 0.1 mo · Listing cliff
Listing is at risk and the usual cures are constrained. Next thing to watch: a reverse-split proxy, a hearings-panel 8-K, or a Form 25.
Key filing: Exchange deficiency notice, Aug 21, 2026 — 8-K Item 3.01 filed 2026-08-21 (accepted 17:00 ET) (filing) - Hearings panel · 2026-08-21: “hearings panel” language in 8-K (8-K) filed 2026-08-21 (filing) - Hearings panel · 2026-09-08: “hearings panel” language in 8-K (8-K) filed 2026-09-08 (filing) - Exchange deficiency notice · 2026-09-08: 8-K Item 3.01 filed 2026-09-08 (accepted 17:25 ET) (filing) Would confirm: Nasdaq 'Pending Suspension' listing, Form 25, hearings-panel denial 8-K, or a reverse-split proxy. · Would invalidate: 8-K announcing regained compliance; equity raise that restores stockholders' equity; MVLS back above threshold for 10+ days.
SKYE · Skye Bioscience, Inc. — Pressure ▼ · Radar 93 · runway 3.8 mo · Forced raise, Listing cliff, Death-spiral watch
The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K.
Key filing: Exchange deficiency notice, Aug 19, 2026 — 8-K Item 3.01 filed 2026-08-19 (accepted 19:56 ET) (filing) - Equity deficiency · 2026-08-19: “stockholders equity deficiency” language in 8-K (8-K) filed 2026-08-19 (filing) - Equity line · 2026-08-24: “equity line” language in 8-K (EX-10.1) filed 2026-08-24 (filing) - Delisting language · 2026-08-19: “delisting notice” language in 8-K (8-K) filed 2026-08-19 (filing) Would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it. · Would invalidate: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).
CWD · CaliberCos Inc. — Pressure ▼ · Radar 92 · runway 2.0 mo · Listing cliff
Listing is at risk and the usual cures are constrained. Next thing to watch: a reverse-split proxy, a hearings-panel 8-K, or a Form 25.
Key filing: Hearings panel, Aug 26, 2026 — “hearings panel” language in 8-K (8-K) filed 2026-08-26 (filing) - Exchange deficiency notice · 2026-08-26: 8-K Item 3.01 filed 2026-08-26 (accepted 17:27 ET) (filing) - Minimum bid deficiency · 2026-08-26: “min bid” language in 8-K (8-K) filed 2026-08-26 (filing) - Delisting language · 2026-08-26: “delisting notice” language in 8-K (8-K) filed 2026-08-26 (filing) Would confirm: Nasdaq 'Pending Suspension' listing, Form 25, hearings-panel denial 8-K, or a reverse-split proxy. · Would invalidate: 8-K announcing regained compliance; equity raise that restores stockholders' equity; MVLS back above threshold for 10+ days.
Support ▲ — insiders and large holders putting their own money in.
KPLT · Katapult Holdings, Inc. — Support ▲ · Radar 86 · runway cash-flow positive · Forced raise, Activist + distress
A new active holder crossed 5% and must state its intentions. Note the pressure side: forced raise setup also active — see the ticker page.
Key filing: New 13D filer, Aug 18, 2026 — Schedule 13D filed 2026-08-18 (filing) - New 13D filer · 2026-08-18: Schedule 13D filed 2026-08-18 (filing) - New 13D filer · 2026-08-18: Schedule 13D filed 2026-08-18 (filing) - Auditor change · 2026-09-04: 8-K Item 4.01 filed 2026-09-04 (accepted 16:05 ET) (filing) Would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it. · Would invalidate: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).
SLE · Super League Enterprise, Inc. — Support ▲ · Radar 87 · runway 8.3 mo · Forced raise, Death-spiral watch, Activist + distress
A new active holder crossed 5% and must state its intentions. Note the pressure side: forced raise setup also active — see the ticker page.
Key filing: New 13D filer, Aug 20, 2026 — Schedule 13D filed 2026-08-20 (filing) - New 13D filer · 2026-08-26: Schedule 13D filed 2026-08-26 (filing) - Offering (424B) · 2026-08-18: 424B5 prospectus supplement 2026-08-18; 0 prior 424B filings in 12m (filing) - Offering (424B) · 2026-08-24: 424B5 prospectus supplement 2026-08-24; 1 prior 424B filings in 12m (filing) Would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it. · Would invalidate: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).
MBRX · Moleculin Biotech, Inc. — Support ▲ · Radar 87 · runway 3.4 mo · Forced raise, Activist + distress
A new active holder crossed 5% and must state its intentions. Note the pressure side: forced raise setup also active — see the ticker page.
Key filing: New 13D filer, Aug 25, 2026 — Schedule 13D filed 2026-08-25 (filing) - New 13D filer · 2026-08-25: Schedule 13D filed 2026-08-25 (filing) - Offering (424B) · 2026-08-21: 424B5 prospectus supplement 2026-08-21; 4 prior 424B filings in 12m (filing) - Share count +25% · 2026-06-30: Shares outstanding 5,336,350 (2026-05-07) -> 19,477,380 (2026-08-06), +265% Would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it. · Would invalidate: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).
DH · Definitive Healthcare Corp. — Support ▲ · Radar 53 · runway n/a
A new active holder crossed 5% and must state its intentions.
Key filing: New 13D filer, Sep 2, 2026 — Schedule 13D filed 2026-09-02 (filing)
PFSA · Profusa, Inc. — Support ▲ · Radar 94 · runway 0.3 mo · Forced raise, Listing cliff, Death-spiral watch, Activist + distress
A new active holder crossed 5% and must state its intentions. Note the pressure side: forced raise setup also active — see the ticker page.
Key filing: New 13D filer, Aug 19, 2026 — Schedule 13D filed 2026-08-19 (filing) - Equity line · 2026-08-21: “equity line” language in 8-K (EX-10.2) filed 2026-08-21 (filing) - Equity line · 2026-09-01: “equity line” language in 8-K (EX-10.1) filed 2026-09-01 (filing) - Exchange deficiency notice · 2026-08-31: 8-K Item 3.01 filed 2026-08-31 (accepted 08:54 ET) (filing) Would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it. · Would invalidate: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).
NXL · Nexalin Technology, Inc. — Support ▲ · Radar 94 · runway 1.7 mo · Forced raise, Listing cliff, Death-spiral watch, Shelf loaded, Activist + distress
A new active holder crossed 5% and must state its intentions. Note the pressure side: forced raise setup also active — see the ticker page.
Key filing: New 13D filer, Sep 3, 2026 — Schedule 13D filed 2026-09-03 (filing) - Equity deficiency · 2026-08-17: “stockholders equity deficiency” language in 8-K (8-K) filed 2026-08-17 (filing) - Equity line · 2026-08-21: “equity line” language in 8-K (EX-10.2) filed 2026-08-21 (filing) - Equity line · 2026-08-20: “equity line” language in 8-K (EX-10.2) filed 2026-08-20 (filing) Would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it. · Would invalidate: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).
Exchange deficiency & delisting notices (3)
Defaults, bankruptcies, control changes (1)
New shelves & offerings (9)
ATMs, equity lines, converts, warrant deals (8)
New Schedule 13D filers (1)
Executive departure clusters (7)
Red-team verdict: publish with caveats · ticker page
What happened. Nexalin Technology, Inc. (NXL) disclosed on August 17, 2026 (8-K Item 3.01) that Nasdaq notified the company of both stockholders' equity deficiency and minimum bid-price non-compliance. The company's balance sheet as of June 30, 2026 reported equity of $1.5 million and cash of $1.0 million against an annualized burn rate of approximately $7.1 million, yielding an estimated runway of 1.7 months (now 76 days stale). Between August 20 and 21, the company executed multiple registered direct and unregistered offerings with attached equity lines, convertible notes, and ATM agreements, then filed a fresh S-1 shelf registration on September 3. On September 2, an executive departure was disclosed (8-K Item 5.02), and on September 3 a new Schedule 13D appeared signaling an activist position exceeding 5%.
What most people will notice. The Nasdaq deficiency notices and multiple financings in quick succession. The company has already reverse-split (August 27 8-K Item 5.03) and the share count rose from 20.6 million (May 7) to 22.0 million (August 10) before those latest raises.
What we noticed. The new shelf registration (S-1, September 3) arrived within days of the activist 13D filing, both events occurring after the company exhausted its near-term capital machinery (equity lines, convertible notes, ATM programs filed August 20–21). The activist entered precisely when the company has no effective cure path for the equity deficiency (equity of $1.5 million versus typical Nasdaq $2.5 million minimum) and has already executed a reverse split within the past 12 months, narrowing the window for a conventional listing cure. The registered-direct and unregistered offerings on August 20–21 featured both equity lines and a convertible note—instruments that can reset or reprice—while the company faces minimum bid compliance pressure, a textbook death-spiral setup.
Why it may matter. The confluence of a fresh activist, imminent cash exhaustion, negative equity deficiency, and variable-priced securities outstanding creates a high-probability path to either a distressed recapitalization or a board-level change of control. The shelf filing immediately after the activist's appearance suggests preparation for a negotiated transaction or preemptive defense. If the convertible note and equity lines begin converting or drawing down while the stock trades near minimum bid thresholds, each conversion will depress the price and accelerate dilution—a self-reinforcing cycle that may force either delisting or a take-under by the activist or another third party.
Evidence. - Nasdaq notified the company on August 14, 2026 of stockholders' equity deficiency (filing) - Nasdaq notified the company of minimum bid-price non-compliance (filing) - Cash of $1,004,958 and equity of $1,519,423 as of June 30, 2026 (filing) - Company executed registered direct offering with equity line and ATM program on August 19–20 (filing) - Convertible note and additional equity line executed August 21 (filing) - S-1 shelf registration filed September 3, 2026 (filing) - Schedule 13D filed September 3, 2026 disclosing activist position >5% (filing) - Reverse split executed August 26, 2026 (8-K Item 5.03 filed August 27) (filing) - Officer departure disclosed September 2, 2026 (8-K Item 5.02) (filing)
What could prove us wrong. The activist 13D/A discloses a passive investment thesis or a position sold down, removing change-of-control risk · The company secures a non-dilutive cash infusion (asset sale, grant, partnership milestone) that extends runway beyond 12 months and permits equity cure · The convertible note and equity lines are repaid or terminated in cash before material conversion, preventing death-spiral mechanics
Would confirm: A 13D/A disclosing Item 4 plans (board seats, merger, recapitalization); DEFC14A proxy materials; 8-K announcing board composition changes; or rising share count in the next 10-Q paired with sub-$1.00 bid price and another reverse-split proxy (DEFM14A or DEF14A). Would invalidate: 8-K announcing Nasdaq compliance regained for both equity and bid price; 13D/A showing the activist exited; equity line and convertible note terminated (8-K Item 1.02); or a 10-Q showing positive operating cash flow and stable share count quarter-over-quarter.
Red-team caveats. - The 1.7-month runway calculation is stale by 76 days (as of June 30, 2026; reviewed mid-September 2026). The company has completed multiple financings since June 30 (August 20-21 registered direct offerings, equity lines, convertible note, ATM programs) that will have extended runway materially, though by an unknown amount until the next 10-Q. - The analysis states 'imminent cash exhaustion' but the staleness combined with the intervening financings means current runway is likely longer than 1.7 months. The note should clarify that the 1.7-month figure predates the August capital raises. - The 'death spiral' mechanism is described as active ('can reset or reprice... while the company faces minimum bid compliance pressure') but the note does not confirm whether the convertible note or equity lines contain variable-pricing or reset provisions. The evidence packet shows these instruments exist but does not excerpt their terms. The note should state this is contingent on the instruments having variable-pricing features. - The statement 'no effective cure path for the equity deficiency' may overstate the constraint: the company has already raised capital multiple times in August and filed a shelf in September, demonstrating access to capital markets. While challenging, a cure path exists if the company can raise enough to restore equity above the threshold.
Red-team verdict: publish with caveats · ticker page
What happened. Profusa (PFSA), a surgical-instrument company with ~$375,000 cash and 0.3 months runway as of 31 March 2026, received its fourth Nasdaq listing notice on 26 August 2026 (8-K filed 31 Aug) and has entered a pair of convertible/equity-line arrangements in rapid succession (12 Aug and 1 Sep 2026). Simultaneously, an activist filed a Schedule 13D on 19 August 2026. The company carries $28.2 million negative equity, $29.0 million current liabilities, and a going-concern opinion (10-Q 19 Aug 2026). Reverse-split language appears in five filings across August and early September 2026, and the company's $1.3 million public float sits well below Nasdaq's $5 million MVLS threshold.
What most people will notice. The critical runway (under one month), fourth listing notice, and multiple reverse-split references signal imminent delisting risk. The activist 13D filing amid extreme financial distress will draw attention to potential board pressure or change-of-control scenarios.
What we noticed. Two separate financing arrangements—both carrying convertible-note, equity-line, and PIPE language—were executed within eleven days (12 Aug and 1 Sep 2026), suggesting sequential tranches rather than a single large commitment. The 21 August 8-K was filed at 16:05 ET on a Friday, classic timing for difficult disclosure. The Schedule 13D arrival (19 Aug) sits between the two financing dates and immediately after the going-concern 10-Q, implying the activist may be a participant in or beneficiary of the distressed-capital stack. The repeated reverse-split mentions in both the definitive proxy (28 Aug, for 18 Sep meeting) and live financing exhibits (21 Aug, 1 Sep) suggest the board is simultaneously managing compliance and enabling further dilution at lower prices.
Why it may matter. The confluence of sub-$400k cash, an activist holder, and two tranches of variable/discount-priced instruments creates a textbook death-spiral setup: each conversion or draw lowers the stock price, which lowers the next conversion price, forcing more shares into the market. With the company already on its fourth deficiency notice and negative equity of $28.2 million, the probability of voluntary or involuntary delisting is high, and any remaining equity value may accrue disproportionately to the new convertible holders and the activist rather than existing public shareholders. The tight sequence of events (10-Q, 13D, two financings, deficiency notice, and proxy for reverse split—all within two weeks in August 2026) indicates orchestrated recapitalization under time pressure.
Evidence. - Cash $375,000 and equity negative $28.2 million as of 31 March 2026 (filing) - 0.3 months runway, derived from $375k cash and $16.2M annual operating cash outflow (filing) - Going-concern opinion affirmed in 10-Q for quarter ended 30 June 2026, filed 19 August 2026 (filing) - Schedule 13D filed 19 August 2026 (filing) - First financing arrangement (equity line, convertible note, PIPE) dated 12 August 2026, disclosed in 8-K filed 21 August 2026 at 16:05 ET (filing) - Second financing arrangement (equity line, convertible note, PIPE) dated 1 September 2026, disclosed in 8-K filed 1 September 2026 (filing) - Nasdaq listing notice (Item 3.01) received 26 August 2026, disclosed in 8-K filed 31 August 2026 (filing) - Public float $1.3 million as of 30 June 2025, below $5M MVLS threshold (filing) - Reverse-split language in definitive proxy (DEF 14A) filed 28 August 2026 for 18 September 2026 meeting (filing) - Current liabilities $29.0 million vs liquidity $375,000 as of 31 March 2026 (filing)
What could prove us wrong. Non-dilutive capital event (asset sale, grant, milestone payment, or strategic partnership) provides multi-quarter runway without issuing equity at depressed prices. · Activist 13D/A discloses the position was sold or reveals a passive investment thesis rather than distressed recapitalization intent. · Company successfully regains compliance with all Nasdaq standards and share count remains flat quarter-over-quarter, indicating no conversions occurred.
Would confirm: Form 424B3 resale prospectus supplements showing rising share count attributable to convertible conversions or equity-line draws; 10-Q for quarter ending 30 September 2026 showing material share-count increase and further cash decline; 13D/A disclosing board representation (Item 4) or operational demands; or Nasdaq 'pending suspension' 8-K (Item 3.01). Would invalidate: 8-K announcing Nasdaq compliance regained; non-dilutive cash infusion restoring positive equity and multi-quarter runway; convertible notes repaid or equity line terminated (8-K Item 1.02); or 13D/A showing activist exit.
Red-team caveats. - Cash and equity figures ($375k, -$28.2M) are as of 31 March 2026, now 167 days stale. The runway calculation is explicitly flagged as stale:167d in the evidence packet. Subsequent financing events in August-September 2026 mean actual current cash position is unknown and likely materially different. - The 'fourth listing notice' claim requires verification. The packet shows one Item 3.01 filing on 31 Aug 2026 and references 'prior_same_item_12m: 4' in metadata, suggesting four total notices in 12 months including this one, not that this is the fourth notice overall. The precise deficiency count and nature should be confirmed from the actual 8-K text. - Public float figure ($1.3M) is as of 30 June 2025, over one year stale, and predates the reverse splits mentioned in August 2026 filings. Current float is unknown and the MVLS comparison may no longer be accurate. - The note describes the financing arrangements as 'convertible/equity-line combo' and implies they are variable/discount-priced instruments creating death-spiral risk, but the actual pricing terms are not provided in the evidence packet. The inference is reasonable given the signal taxonomy but the specific conversion mechanics should be verified from the EX-10 exhibits. - The characterization of the activist as 'may be a participant in or beneficiary of the distressed-capital stack' is speculative inference from timing, not evidenced by the 13D filing itself. The 13D URL points to the filing but no excerpt is provided showing the holder's identity, stake size, or intent.
Red-team verdict: publish with caveats · ticker page
What happened. On August 25, 2026, Datavault AI disclosed in an 8-K that it has requested a hearing before a Nasdaq Hearings Panel regarding continued listing deficiencies (Item 3.01). This follows a sequence of financing events on August 18-19: the company filed a 424B5 takedown (its tenth 424B filing in 12 months), disclosed a convertible note structure in 8-K exhibits, and reported three unregistered sales via Item 3.02 8-Ks. The most recent 10-Q for the quarter ended June 30, 2026 (filed August 19) reiterated going-concern language and showed $2.2 million cash against $23.0 million current liabilities and a $23.6 million annual burn rate—implying approximately 1.1 months of runway as of March 31, 2026 (now 167 days stale).
What most people will notice. The hearings-panel request is the headline: Datavault is now in the final administrative stage before potential delisting, with multiple references to minimum-bid deficiencies and reverse-split language across the August filings. Investors will also see the company executed another equity raise via prospectus supplement in mid-August, the latest in a string of ten 424B filings over the prior 12 months.
What we noticed. The company disclosed both ATM program language and convertible note language in the same August 19 8-K filing package (accession 0001104659-26-098494), and separately filed a 424B5 takedown the same day. This suggests multiple parallel financing channels are active simultaneously—an ATM for continuous dribble sales, a convertible structure for institutional participation, and registered direct/PIPE language in the exhibits. The convertible note exhibit (EX-5.1) and PIPE agreement (EX-10.1) appeared in the same 8-K that disclosed a new financial obligation (Item 2.03), the third such Item 2.03 filing in the past 12 months. Additionally, share count jumped 39% between March 17 (614 million shares) and May 11 (856 million shares), yet the most recent balance-sheet data is from March 31—meaning the dilution wave hit after the last reported equity figure of $220 million. The cash and runway figures cannot reflect the capital raised or shares issued after March.
Why it may matter. The confluence of a hearings-panel escalation, sub-two-month runway (on stale data), and active convertible/ATM structures creates a forced-raise scenario with limited negotiating leverage. If the panel denies the appeal or imposes conditions the company cannot meet, the convertible and ATM mechanisms may accelerate dilution precisely when the stock is under minimum-bid pressure—a classic death-spiral setup. The 39% share-count jump and repeated reverse-split references indicate the company has already burned through prior equity cushions, and the June 30 balance sheet (once filed or updated) will likely show materially worse liquidity and equity positions than the stale March figures suggest.
Evidence. - Hearings panel requested on August 25, 2026 (filing) - 424B5 takedown filed August 19, 2026; tenth 424B in 12 months (filing) - Convertible note and PIPE language in 8-K filed August 19, 2026 (filing) - Going concern in 10-Q for quarter ended June 30, 2026 (filing) - Cash $2.2M, current liabilities $23.0M, burn ~$23.6M/yr as of March 31, 2026 (167 days stale) (filing) - Share count grew 39%: 614.3M (March 17) to 855.6M (May 11) (filing) - Three unregistered sales (Item 3.02) on August 19, 2026 (filing) - Reverse split language in August 19 and August 25 8-Ks (filing)
What could prove us wrong. A non-dilutive liquidity event (asset sale, strategic partnership with upfront cash, grant or milestone payment) eliminates near-term financing pressure and renders the convertible/ATM mechanics less relevant. · The June 30, 2026 balance sheet (in the August 19 10-Q) or a subsequent 8-K discloses materially higher cash and lower burn than the stale March data, extending runway well beyond the computed 1.1 months. · Nasdaq grants a compliance extension or the company cures the minimum-bid deficiency (via sustained price recovery or approved reverse split), removing the delisting threat and reducing the urgency of discount capital raises.
Would confirm: Form 4 insider purchases ahead of a new 424B5; another Item 2.03 8-K disclosing draws on the convertible or ATM; or a hearings-panel denial 8-K followed by Form 25 notice of delisting. Would invalidate: 8-K announcing Nasdaq compliance regained; equity or assets materially above liabilities on next 10-Q; share count flat or declining quarter-over-quarter; or 8-K Item 1.02 terminating the ATM or repaying the convertible in cash.
Red-team caveats. - The runway calculation (1.1 months) is based on March 31, 2026 data that is now 167 days stale. The note acknowledges staleness but should more prominently flag that the August 19 10-Q for Q2 2026 (ending June 30) has been filed and likely contains materially updated cash, equity, and runway figures that are not reflected in this analysis. - The claim that 'share count jumped 39% between March 17 (614M) and May 11 (856M)' uses dates that straddle the March 31 balance sheet date, creating ambiguity about which equity figure ($220M) corresponds to which share count. The note should clarify that the March 31 equity of $220M predates the May 11 share count. - The 'tenth 424B filing in 12 months' is cited as evidence of repeated takedowns, but the base rate for takedown signals is 11.25%—relatively common. The note should acknowledge that frequent 424B filings are not unusual for small-cap companies with active shelf programs. - The phrase 'classic death-spiral setup' is strong language. While the death_spiral chain has 0.7 strength, the note should add a caveat that actual death-spiral mechanics depend on conversion terms (floor price, lookback period, reset frequency) not visible in the excerpts provided.
Red-team verdict: publish with caveats · ticker page
What happened. GeoVax disclosed on Aug. 28, 2026 (8-K, Item 3.01) receipt of a Nasdaq Staff Determination Letter stating the company no longer complies with the minimum stockholders' equity rule and the minimum bid price requirement, and that its securities are subject to delisting. The company has requested a hearings panel, which stays the suspension pending the panel's decision. Concurrently, on Aug. 25–28, GeoVax closed an unregistered securities transaction (8-K, Item 3.02) and entered an equity purchase agreement (equity line) with Triton Funds, permitting up to $5 million in future sales, along with warrant inducements that triggered a 1‑for‑25 reverse stock split on Aug. 27. The company's most recent balance sheet (10-Q for Q2 2026, June 30) shows cash of $3.14 million, stockholders' equity of $1.76 million, and an annualized operating cash burn of approximately $14.6 million, implying a runway of 2.6 months—though that balance sheet is now 76 days stale and predates the August financing and reverse split.
What most people will notice. A biotech with less than three months of cash has received formal Nasdaq delisting notices for both equity deficiency and minimum bid price non-compliance, and is now in the hearings-panel stage. The company executed a large reverse split (1‑for‑25) and immediately put in place an equity line, signaling an imminent need to raise capital at what are likely to be deeply discounted terms.
What we noticed. The sequence is striking: the warrant-inducement and equity-line agreements (filed Aug. 28, period ending Aug. 25) were signed before the Staff Determination 8-K (filed Aug. 28, period ending Aug. 27). In other words, management secured additional selling machinery—and induced existing warrant holders to exercise early—on the eve of, or simultaneous with, receiving formal delisting language. The reverse split reduced the share count from 3.47 million (May 14) to 7.37 million (July 27 post-split basis), yet the latest 10-Q still reflects pre-event equity of only $1.76 million; the August unregistered sale and warrant exercises are not yet captured. Given that Nasdaq's 2026 rules permit only one reverse split per 12-month period and impose a $5 million market-value-of-listed-securities floor (effective Sept. 2026, with no cure period), GeoVax has now used its one allowable split and remains subject to both the equity and bid-price deficiencies while the hearings process unfolds. A definitive proxy (DEF 14A, filed Sept. 10) proposes another reverse split of up to 1‑for‑50, suggesting management anticipates needing a second split—but that would require either a rule waiver or a 12-month wait, neither of which aligns with a sub-three-month runway.
Why it may matter. The interplay of a critical cash position, negative compliance status, exhausted reverse-split capacity under current rules, and live discount-pricing instruments (equity line, warrant inducements) creates the setup for a forced, dilutive capital raise on unfavorable terms. If the hearings panel denies the company's request or imposes conditions GeoVax cannot meet before cash runs out, the equity line and any additional warrant exercises will likely be executed at depressed prices, accelerating share-count growth and potentially triggering a self-reinforcing downward spiral in the stock price. Alternatively, if no capital materializes, the company faces suspension and a possible over-the-counter downlist, which would severely impair liquidity and access to institutional capital.
Evidence. - Nasdaq Staff Determination for equity deficiency and minimum bid price, hearings panel requested (filing) - Unregistered securities sale closed Aug. 25–27, 2026 (Item 3.02) (filing) - Equity purchase agreement (equity line) with Triton Funds, up to $5M (filing) - Warrant inducement and 1-for-25 reverse split effective Aug. 27, 2026 (filing) - Cash $3.14M, equity $1.76M, ~2.6 month runway as of June 30, 2026 (10-Q) (filing) - Share count 3.47M (May 14) increased to 7.37M post-split (July 27) (filing) - Definitive proxy (Sept. 10) proposes further reverse split up to 1-for-50 (filing)
What could prove us wrong. GeoVax announces a large non-dilutive cash infusion (grant, milestone payment, or asset sale) that extends runway beyond 12 months and permits compliance without further equity issuance. · The hearings panel grants an extension or waiver permitting a second reverse split within 12 months, and the company simultaneously cures the equity deficiency through a priced offering that attracts institutional demand at or above recent trading levels. · Operating cash flow turns sharply positive (e.g., a partnered product launches and generates immediate royalties), eliminating the need to tap the equity line or issue additional shares.
Would confirm: Next 10-Q (Q3 2026) showing a material increase in share count and decreased cash per share; Form 424B5 or 424B3 prospectus supplement detailing sales under the equity line; or an 8-K announcing hearings-panel denial and formal delisting. Would invalidate: 8-K (Item 3.01) announcing Nasdaq compliance regained for both equity and bid price; termination of the equity line (Item 1.02 8-K); or Q3 10-Q showing stable or declining share count and cash balance materially above June 30 levels without corresponding liabilities.
Red-team caveats. - The note states 'management secured additional selling machinery...on the eve of, or simultaneous with, receiving formal delisting language' - the precise timing sequence cannot be definitively established from public filings alone; both 8-Ks were filed Aug. 28 with different period-ending dates, but internal receipt/decision dates are not disclosed. - The runway calculation (2.6 months) is 76 days stale as of the analysis date and explicitly predates the August financing events; actual current runway is unknown and could be materially different given warrant exercises and any equity-line draws since June 30. - The statement 'Nasdaq's 2026 rules permit only one reverse split per 12-month period' should clarify this is a Nasdaq policy effective 2026 per the analyst's framing, but the specific rule citation is not provided in the evidence packet. - The claim about '$5 million market-value-of-listed-securities floor (effective Sept. 2026, with no cure period)' references a future rule change; confirm whether this rule was actually in effect at the time of the determination letter (Aug. 27, 2026).
Red-team verdict: publish with caveats · ticker page
What happened. On September 2, 2026, Senti disclosed that Nasdaq had notified the company on August 27, 2026 of delisting determinations for failing minimum bid, stockholders' equity, and market value of listed securities (MVLS) requirements; the company requested a hearings panel. With approximately $6.5 million in cash as of June 30, 2026, and an estimated 3.5-month runway based on annualized H1 2026 operating cash outflow of $44 million, Senti executed a series of convertible note amendments and equity commitment letters on September 3, 2026 (filed September 4). The company also filed an S-3/A on September 10, 2026 referencing an at-the-market (ATM) program in the prospectus supplement, indicating multiple channels for near-term equity sales.
What most people will notice. The company faces simultaneous Nasdaq delisting proceedings on three grounds—minimum bid price, equity deficiency, and MVLS—and has requested a hearings panel, a standard last-step before suspension. With only 3.5 months of cash remaining, investors will focus on imminent dilutive financing and the risk of a forced sale or reverse split to cure listing deficiencies.
What we noticed. The convertible note amendments and equity commitment letters filed September 4, 2026 (Accession 0001628280-26-060600) reference PIPE transactions and contain language about stockholders' equity deficiency, suggesting these agreements were negotiated in direct response to the August 27 Nasdaq notice. The timing—just two days after the delisting notice 8-K—and the bundling of multiple financing instruments (convertible notes, equity commitment, ATM shelf) imply the company is executing a coordinated capital strategy rather than ad hoc raises. The equity commitment letter (EX-10.2) explicitly recites the equity deficiency context, indicating the investor demanded structural protections tied to the Nasdaq compliance issue. The convertible notes likely carry discount or anti-dilution ratchets typical of distressed microcap financings.
Why it may matter. The convergence of all three Nasdaq deficiencies (bid, equity, MVLS) while the company is in critical runway territory creates a textbook forced-raise scenario with little bargaining power; any convertible or equity line priced at a discount or with reset provisions can trigger a death spiral if the stock remains under pressure. Under Nasdaq's 2026 rules (one reverse split per 12 months, immediate suspension upon denial of panel appeal), the company has narrower cure options and a tighter timeline than in prior years. If the panel is not granted or the hearing is scheduled beyond the company's cash-out date, Senti may be forced to accept deeply dilutive terms or face suspension while still needing capital.
Evidence. - Nasdaq notified Senti on August 27, 2026 of delisting determinations for minimum bid, equity deficiency, and MVLS non-compliance; company requested hearings panel (filing) - Senti had $6.463 million in cash as of June 30, 2026 (filing) - Estimated 3.5-month runway based on annualized H1 2026 operating cash flow of -$44.1 million (filing) - Convertible note amendment and equity commitment letter executed September 3, 2026 (filed September 4, 2026) (filing) - S-3/A filed September 10, 2026 references ATM program in prospectus supplement (filing) - Equity commitment letter (EX-10.2) recites stockholders' equity deficiency context (filing) - Stockholders' equity was negative $3.4 million as of June 30, 2026 (filing)
What could prove us wrong. The hearings panel grants a cure period and the company receives a non-dilutive cash infusion (asset sale, milestone payment, or grant) sufficient to restore positive equity and extend runway beyond 12 months, obviating forced discount raises. · The convertible notes and equity commitment are structured with fixed floors and no anti-dilution ratchets, preventing downward price spirals even if the stock declines further. · Nasdaq grants compliance relief or the company completes a qualifying reverse split and equity raise that simultaneously cures all three deficiencies (bid, equity, MVLS) before the panel hearing, mooting the delisting threat.
Would confirm: Next 10-Q (for quarter ending September 30, 2026) showing material increases in shares outstanding, disclosure of ATM or convertible note sales, or a subsequent 8-K announcing an offering or pricing of securities under the equity commitment; alternatively, an 8-K disclosing panel hearing results or a proxy statement for a reverse split. Would invalidate: An 8-K announcing regained compliance on all three Nasdaq standards, non-dilutive financing (e.g., strategic partnership with upfront milestone), or repayment/termination of convertible notes in cash; alternatively, operating cash flow turning positive in the next 10-Q, eliminating near-term liquidity pressure.
Red-team caveats. - The cash figure ($6.463M) and runway calculation (3.5 months) are 76 days stale as of the note date (September 11, 2026), based on June 30, 2026 financials. Any financing activity between June 30 and the delisting notice (August 27) or subsequent financings through September 11 would materially affect the runway calculation and should be disclosed as a staleness risk. - The claim that convertible notes 'likely carry discount or anti-dilution ratchets typical of distressed microcap financings' is speculative. The evidence packet shows convertible note amendments were filed, but the actual pricing terms, conversion discounts, or reset provisions are not quoted from the exhibits. This should be flagged as an inference rather than documented fact. - The statement 'Under Nasdaq's 2026 rules (one reverse split per 12 months, immediate suspension upon denial of panel appeal)' references rule changes that are not documented in the evidence packet. If these are real 2026 Nasdaq rule changes, cite the rule amendment; if hypothetical (given the 2026 date context), clarify that the rule framework is assumed. - The note states the equity commitment letter 'explicitly recites the equity deficiency context' but does not quote the relevant language. The evidence URL points to the exhibit, but without a textual excerpt showing structural protections or deficiency-linked conditions, this claim should be softened to 'references' or 'discusses' rather than 'explicitly recites.' - The 'death spiral' chain has a 0.7 strength score and the note states convertible notes 'likely' have ratchets, but the packet does not contain evidence of variable-priced or floating conversion terms. The death-spiral thesis should be presented as a risk scenario contingent on conversion mechanics that are not fully documented, not as established fact.
Quiet Alpha is an automated financial research publication. It is not investment advice, not a recommendation to buy or sell any security, and not personalized to any reader. Data are derived from public SEC filings and may contain errors; verify against the source documents linked in each item. Quiet Alpha accepts no compensation from issuers. Microcap securities are illiquid and can lose most or all of their value.